Barclays Initiates Coverage on Cardinal Health (CAH) with Overweight Rating

Group 1 - Cardinal Health, Inc. (NYSE:CAH) is recognized as one of the 15 Best Stocks to Buy for the Long Term [1] - Barclays initiated coverage on Cardinal Health with an Overweight rating and a price target of $243, expressing optimism particularly about drug distributors within the US healthcare technology and distribution space [2] - The stock has increased nearly 68% since the beginning of 2025, reflecting the company's transformation towards higher-margin areas, especially in specialty pharmaceuticals and managed services [3] Group 2 - In fiscal Q1 2026, Cardinal Health's revenue from the Pharmaceutical and Specialty Solutions segment rose 23% to $59.2 billion, driven by strong brand and specialty drug sales [3] - Total revenue for the quarter reached $64 billion, marking a 22% increase from the previous year, and the company completed the acquisition of Solaris Health, enhancing its scale in the urology sector [4] - Cardinal Health is one of the largest healthcare services and products companies in the US, supplying pharmaceuticals and medical equipment to a diverse range of providers [5]